脑肿瘤起始细胞对替莫唑胺的敏感性。
Sensitivity to temozolomide in brain tumor initiating cells.
机构信息
Department of Clinical Neurosciences, Foothills Medical Centre, 1403 29th St NW, Calgary, Alberta, Canada.
出版信息
Neuro Oncol. 2010 Jul;12(7):756-60. doi: 10.1093/neuonc/noq032. Epub 2010 Apr 13.
Abstract
Molecular alterations in glioblastoma have the potential to guide treatment. Here, we explore the relationship between temozolomide (TMZ) response and O(6)-methylguanine DNA methyltransferase (MGMT) status in brain tumor initiating cells (BTICs). Methylation, expression, and sensitivity were assessed in 20 lines; associations were evaluated by Fisher's exact test. Some BTICs were sensitive. Sensitivity to TMZ was only associated with protein expression (P = .001). There were atypical BTICs including TMZ-resistant lines in which the methylation-specific PCR reaction revealed both methylated and unmethylated bands. BTICs are not uniformly resistant to TMZ; some are sensitive. MGMT status does not predict TMZ response with high precision.
摘要
胶质母细胞瘤中的分子改变有可能指导治疗。在这里，我们探讨了替莫唑胺（TMZ）反应与脑肿瘤起始细胞（BTIC）中 O(6)-甲基鸟嘌呤 DNA 甲基转移酶（MGMT）状态之间的关系。在 20 条系中评估了甲基化、表达和敏感性；通过 Fisher 精确检验评估关联。一些 BTICs 对 TMZ 敏感。对 TMZ 的敏感性仅与蛋白表达相关（P =.001）。存在非典型 BTICs，包括 TMZ 耐药系，其中甲基化特异性 PCR 反应显示出甲基化和非甲基化条带。BTICs 对 TMZ 并非普遍耐药；有些 BTICs 对 TMZ 敏感。MGMT 状态并不能高精度预测 TMZ 反应。
相似文献
1
Sensitivity to temozolomide in brain tumor initiating cells.脑肿瘤起始细胞对替莫唑胺的敏感性。
Neuro Oncol. 2010 Jul;12(7):756-60. doi: 10.1093/neuonc/noq032. Epub 2010 Apr 13.
2
Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.异常 p53 功能对替莫唑胺敏感性的影响胶质母细胞瘤细胞系和脑肿瘤起始细胞。
J Neurooncol. 2011 Mar;102(1):1-7. doi: 10.1007/s11060-010-0283-9. Epub 2010 Jul 1.
3
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.原位胶质母细胞瘤异种移植模型中MGMT启动子甲基化状态的评估及其与替莫唑胺反应的相关性
J Neurooncol. 2009 Mar;92(1):23-31. doi: 10.1007/s11060-008-9737-8. Epub 2008 Nov 15.
4
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.临床试验证实了O-6-甲基鸟嘌呤-DNA甲基转移酶启动子甲基化在接受替莫唑胺治疗的胶质母细胞瘤患者中的预测价值。
Clin Cancer Res. 2004 Mar 15;10(6):1871-4. doi: 10.1158/1078-0432.ccr-03-0384.
5
Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.MGMT 蛋白缺失以及 MGMT 启动子甲基化预测替莫唑胺的敏感性。
Br J Cancer. 2010 Jun 29;103(1):29-35. doi: 10.1038/sj.bjc.6605712. Epub 2010 Jun 1.
6
Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.替莫唑胺的放射增敏作用仅在一部分O6-甲基鸟嘌呤-DNA甲基转移酶甲基化的多形性胶质母细胞瘤异种移植物中在体内观察到。
Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):212-9. doi: 10.1016/j.ijrobp.2009.04.026.
7
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子甲基化与儿童胶质母细胞瘤的生存获益及对替莫唑胺的敏感性相关。
Pediatr Blood Cancer. 2007 Apr;48(4):403-7. doi: 10.1002/pbc.20803.
8
Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.替莫唑胺长期治疗是新诊断胶质母细胞瘤的一种可行选择：一家机构多达101个替莫唑胺疗程的经验。
Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.
9
Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.替莫唑胺联合 MGMT 基因状态的抗胶质瘤治疗。
Anticancer Res. 2009 Nov;29(11):4845-54.
10
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.组蛋白去甲基化酶KDM5A是胶质母细胞瘤中对替莫唑胺耐药的关键因素。
Cell Cycle. 2015;14(21):3418-29. doi: 10.1080/15384101.2015.1090063.
引用本文的文献
1
Isovalerylspiramycin I Reprograms the Immunosuppressive and Temozolomide-Resistant Microenvironment by Inhibiting the Frizzled-5/Wnt/β-Catenin Pathway in Glioblastoma.异戊酰螺旋霉素I通过抑制胶质母细胞瘤中的卷曲蛋白-5/ Wnt/β-连环蛋白信号通路来重塑免疫抑制和耐替莫唑胺的微环境。
Research (Wash D C). 2025 Aug 13;8:0828. doi: 10.34133/research.0828. eCollection 2025.
2
Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells.溶瘤单纯疱疹病毒治疗脑胶质瘤和靶向脑胶质瘤干细胞。
Front Cell Infect Microbiol. 2023 May 31;13:1206111. doi: 10.3389/fcimb.2023.1206111. eCollection 2023.
3
Targeting Glioblastoma Stem Cells to Overcome Chemoresistance: An Overview of Current Therapeutic Strategies.靶向胶质母细胞瘤干细胞以克服化疗耐药性：当前治疗策略概述
Biomedicines. 2022 Jun 2;10(6):1308. doi: 10.3390/biomedicines10061308.
4
Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells.新型多巴胺受体 3 拮抗剂抑制原代和替莫唑胺耐药胶质母细胞瘤细胞的生长。
PLoS One. 2021 May 4;16(5):e0250649. doi: 10.1371/journal.pone.0250649. eCollection 2021.
5
Targeting Glioma Stem Cells.靶向神经胶质瘤干细胞。
Neurosurg Clin N Am. 2021 Apr;32(2):283-289. doi: 10.1016/j.nec.2021.01.002. Epub 2021 Feb 18.
6
The Subventricular Zone, a Hideout for Adult and Pediatric High-Grade Glioma Stem Cells.室管膜下区，成人和儿童高级别胶质瘤干细胞的藏身之处。
Front Oncol. 2021 Jan 26;10:614930. doi: 10.3389/fonc.2020.614930. eCollection 2020.
7
Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression.胶质母细胞瘤衍生的白细胞介素 33 调控炎症性脑肿瘤微环境，从而加速胶质母细胞瘤的进展。
Nat Commun. 2020 Oct 5;11(1):4997. doi: 10.1038/s41467-020-18569-4.
8
Discovery of a new pyrimidine synthesis inhibitor eradicating glioblastoma-initiating cells.发现一种新的嘧啶合成抑制剂，能根除神经胶质瘤起始细胞。
Neuro Oncol. 2020 Feb 20;22(2):229-239. doi: 10.1093/neuonc/noz170.
9
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma.治疗初发胶质母细胞瘤患者特异性药物敏感性的肿瘤间异质性。
BMC Cancer. 2019 Jun 25;19(1):628. doi: 10.1186/s12885-019-5861-4.
10
20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.20(S)-人参皂苷 Rg3 逆转替莫唑胺耐药并抑制胶质母细胞瘤中上皮-间充质转化的进展。
Cancer Sci. 2019 Jan;110(1):389-400. doi: 10.1111/cas.13881. Epub 2018 Dec 14.
本文引用的文献
1
MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.MSH6突变在替莫唑胺治疗期间出现在胶质母细胞瘤中，并介导替莫唑胺耐药。
Clin Cancer Res. 2009 Jul 15;15(14):4622-9. doi: 10.1158/1078-0432.CCR-08-3012. Epub 2009 Jul 7.
2
Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.人胶质母细胞瘤干细胞的增殖不依赖于外源性有丝分裂原。
Stem Cells. 2009 Aug;27(8):1722-33. doi: 10.1002/stem.98.
3
Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution.不同的癌症干细胞样细胞群共存于人类胶质母细胞瘤中，并表现出不同的致瘤性和独立的基因组进化。
Oncogene. 2009 Apr 16;28(15):1807-11. doi: 10.1038/onc.2009.27. Epub 2009 Mar 16.
4
Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.胶质母细胞瘤中与MGMT启动子甲基化和基因表达相关区域的鉴定。
Neuro Oncol. 2009 Aug;11(4):348-56. doi: 10.1215/15228517-2009-001. Epub 2009 Feb 17.
5
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.原位胶质母细胞瘤异种移植模型中MGMT启动子甲基化状态的评估及其与替莫唑胺反应的相关性
J Neurooncol. 2009 Mar;92(1):23-31. doi: 10.1007/s11060-008-9737-8. Epub 2008 Nov 15.
6
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.全面的基因组特征分析确定了人类胶质母细胞瘤的基因和核心通路。
Nature. 2008 Oct 23;455(7216):1061-8. doi: 10.1038/nature07385. Epub 2008 Sep 4.
7
Temozolomide preferentially depletes cancer stem cells in glioblastoma.替莫唑胺优先清除胶质母细胞瘤中的癌症干细胞。
Cancer Res. 2008 Jul 15;68(14):5706-15. doi: 10.1158/0008-5472.CAN-07-6878.
8
Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.多形性胶质母细胞瘤中抗O6-甲基鸟嘌呤-甲基转移酶（MGMT）免疫组化：观察者间差异及与患者生存率缺乏相关性阻碍其作为临床生物标志物的应用。
Brain Pathol. 2008 Oct;18(4):520-32. doi: 10.1111/j.1750-3639.2008.00153.x. Epub 2008 Apr 8.
9
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.新诊断的不可手术的胶质母细胞瘤患者接受新辅助替莫唑胺治疗时，O6-甲基鸟嘌呤-DNA甲基转移酶与生存的相关性
J Clin Oncol. 2007 Apr 20;25(12):1470-5. doi: 10.1200/JCO.2006.07.4807.
10
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.美国临床肿瘤学会/美国病理学家学会关于乳腺癌中人表皮生长因子受体2检测的指南建议
J Clin Oncol. 2007 Jan 1;25(1):118-45. doi: 10.1200/JCO.2006.09.2775. Epub 2006 Dec 11.
Zotero 插件